{"DataElement":{"publicId":"2005481","version":"4","preferredName":"Common Toxicity Criteria Adverse Event Glaucoma Grade","preferredDefinition":"in CTC category Ocular/Visual, assessment of the severity of a glaucoma adverse event using a graded scale.","longName":"CTC_AE_GLAUCOMA_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2192537","version":"1","preferredName":"Common Toxicity Criteria Adverse Events Glaucoma","preferredDefinition":"information related to the CTC adverse event of glaucoma.","longName":"CTC_AE_GLAUCOMA","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2192535","version":"1","preferredName":"Glaucoma","preferredDefinition":"An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)","longName":"Glaucoma","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Glaucoma","conceptCode":"C26782","definition":"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9F4C3B9-90E3-0989-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9F4C3B9-90E9-0989-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017681","version":"3","preferredName":"Common Toxicity Criteria Adverse Event Glaucoma Grade","preferredDefinition":"in CTC category Ocular/Visual, assessment of the severity of a glaucoma adverse event using a graded scale.","longName":"CTC_AE_GLAUCOMA_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":"Elevated intraocular pressure (EIOP) with single topical agent for intervention, no visual field deficit","ValueMeaning":{"publicId":"2566376","version":"1","preferredName":"Elevated intraocular pressure (EIOP) with single topical agent for intervention, no visual field deficit","longName":"2566376","preferredDefinition":"Elevated intraocular pressure (EIOP) with single topical agent for intervention, no visual field deficit","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D055-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-08","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C462BFD6-360D-72EA-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"EIOP causing early visual field deficit (i.e., nasal step or arcuate deficit); multiple topical or oral agents indicated","ValueMeaning":{"publicId":"2566377","version":"1","preferredName":"EIOP causing early visual field deficit (i.e., nasal step or arcuate deficit); multiple topical or oral agents indicated","longName":"2566377","preferredDefinition":"EIOP causing early visual field deficit (i.e., nasal step or arcuate deficit); multiple topical or oral agents indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D056-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-08","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C462BFD6-360F-72EA-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"EIOP causing marked visual field deficits (i.e., involving both superior and inferior visual fields); operative intervention indicated","ValueMeaning":{"publicId":"2566378","version":"1","preferredName":"EIOP causing marked visual field deficits (i.e., involving both superior and inferior visual fields); operative intervention indicated","longName":"2566378","preferredDefinition":"EIOP causing marked visual field deficits (i.e., involving both superior and inferior visual fields); operative intervention indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D057-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-08","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C462BFD6-3611-72EA-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"EIOP resulting in blindness (20/200 or worse); enucleation indicated","ValueMeaning":{"publicId":"2566379","version":"1","preferredName":"EIOP resulting in blindness (20/200 or worse); enucleation indicated","longName":"2566379","preferredDefinition":"EIOP resulting in blindness (20/200 or worse); enucleation indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D058-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-08","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C462BFD6-3613-72EA-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C462BFD6-3615-72EA-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C462BFD6-3607-72EA-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-08","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Glaucoma Gr","type":"Preferred Question Text","description":"CTC Adverse Event Glaucoma Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Glaucoma Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C46298C2-1424-72EC-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-11-29","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-08","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}